Apostrophe

Apostrophe, Inc. is a healthcare technology company that specializes in personalized skincare solutions, offering customized dermatology treatments primarily through a fully digital platform. Founded in 2012, Apostrophe, Inc. is headquartered in Oakland, US, and focuses on providing personalized skincare solutions.

The company was acquired by Hims & Hers Health, Inc. in June 2021 from Nelstone Ventures, FJ Labs, and SignalFire. The acquisition aimed to enhance the delivery of advanced dermatology treatments. Apostrophe's CEO is Ben Holber, who is also one of the co-founders alongside Chris Minnich, Jamaal Young, Linda Nidle, and Ryan Hambley.

The company has engaged in five investment deals, with the most recent funding round being a Seed round in June 2021, raising a total of USD 6. 00 mn, led by SignalFire and included investors like FJ Labs. This total amount raised matches the latest round amount. Apostrophe provides a variety of personalized skincare treatments specifically tailored for women, addressing issues such as wrinkles, acne, dark spots, and overall skin health.

Their core offerings consist of customized prescription gel creams along with quality over-the-counter products developed with clinical expertise. The firm emphasizes a fully digital experience, allowing for 100% online support and direct delivery, catering to the demand for accessible skincare solutions in the North American market. Apostrophe operates on a direct-to-consumer model, primarily conducting transactions via their online platform. Products can be purchased individually, starting at USD 15, ensuring easy access to personalized skincare solutions.

This model focuses on individual sales rather than subscriptions or partnerships, although bundled offerings may be available. Key products include prescription skincare treatments and anti-aging creams, designed for a wide audience in the skincare market, while the pricing strategy seeks to balance affordability with high-quality standards. With the acquisition finalized in June 2021, Apostrophe, Inc. plans to leverage the resources of Hims & Hers Health, Inc.

to broaden its range of dermatology treatments and enhance service delivery. Future initiatives include the design and launch of new personalized skincare products to meet evolving customer needs. The company aims to expand its market presence beyond North America, targeting specific growth in European and Asian markets by 2023. Funding from the latest Seed round will support these expansions and product development efforts, allowing Apostrophe to scale operations and improve consumer access to personalized skincare.